Urologic Imaging

What Imaging Should You Order for Suspected Testicular Cancer Recurrence?

·
What Imaging Should You Order for Suspected Testicular Cancer Recurrence?

A 28-year-old man arrives for a follow-up appointment. Six months ago, he underwent a right radical orchiectomy for a stage IB nonseminoma and opted for active surveillance. His tumor markers have been stable, but for the past three weeks, he’s had a persistent, dry cough. You are concerned about a potential recurrence, and the first decision is which imaging study to order. This scenario requires a deliberate, stepwise approach to confirm or exclude metastatic disease while minimizing unnecessary radiation. According to the American College of Radiology (ACR) Appropriateness Criteria, the initial imaging study for this presentation is `Radiography chest`, which is rated as Usually appropriate.

Who Fits This Clinical Scenario?

This imaging workflow is specifically for patients with a confirmed diagnosis of stage IA or IB pure seminoma or nonseminomatous germ cell tumor (NSGCT) who have already undergone radical orchiectomy and are on an active surveillance protocol. The key trigger for this pathway is a new clinical suspicion of recurrence. This suspicion can arise from several sources:

  • New Symptoms: The patient presents with new, persistent symptoms such as a cough, shortness of breath, hemoptysis (suggesting pulmonary metastases), back or flank pain (suggesting retroperitoneal adenopathy), or neurologic symptoms.
  • Abnormal Physical Exam: A newly palpable abdominal mass or supraclavicular lymphadenopathy.
  • Rising Tumor Markers: An elevation in serum tumor markers (alpha-fetoprotein [AFP], beta-human chorionic gonadotropin [β-hCG], or lactate dehydrogenase [LDH]) above the baseline established post-orchiectomy.

This guidance does not apply to patients undergoing initial staging immediately after diagnosis, as that requires a more comprehensive baseline evaluation. It also excludes patients with higher-stage disease (stage II or III) at initial diagnosis or those on routine surveillance imaging schedules without any new signs, symptoms, or marker elevation. Those scenarios follow different ACR-recommended pathways.

What Diagnoses Are You Working Up in This Scenario?

When a patient on surveillance for early-stage testicular cancer develops new symptoms, the primary goal of imaging is to identify the location and extent of potential recurrence. The differential diagnosis is focused and driven by the known patterns of metastatic spread for germ cell tumors.

Pulmonary Metastases
This is the most common site of distant (hematogenous) spread for both seminoma and nonseminoma. A new cough or dyspnea is highly concerning for lung parenchymal or pleural-based nodules. Imaging is critical to detect these lesions, which often appear as well-defined, round opacities of varying sizes, typically in the lung bases.

Retroperitoneal Lymphadenopathy
This is the most common site of recurrence overall, representing the primary lymphatic drainage basin for the testes. While a patient may present with back or abdominal pain, retroperitoneal disease can also be clinically silent, even with rising tumor markers. Imaging must be able to accurately assess the retroperitoneal lymph nodes, particularly in the para-aortic and interaortocaval regions.

Mediastinal or Hilar Lymphadenopathy
The mediastinum is another common site for lymphatic spread, often occurring in conjunction with retroperitoneal or pulmonary disease. Enlarged lymph nodes in the hila or mediastinum can cause symptoms like coughing or chest pressure. Imaging helps differentiate this from primary lung parenchymal disease.

Benign Etiology
It is crucial to remember that a young, otherwise healthy individual can develop common intercurrent illnesses. The patient’s cough could be from a simple viral bronchitis or community-acquired pneumonia. The initial imaging study helps distinguish between a benign, self-limited process and a more ominous finding requiring oncologic intervention.

Why Is a Chest Radiograph the Recommended First Study?

In a patient with suspected recurrence of testicular cancer, particularly with new pulmonary symptoms, the ACR designates `Radiography chest` as Usually appropriate. This recommendation is based on a balance of diagnostic yield, radiation safety, and clinical workflow efficiency.

A chest radiograph serves as an excellent initial screening tool. It is highly effective for detecting clinically significant pulmonary metastases, which are the most common form of distant spread. While less sensitive than computed tomography (CT) for sub-centimeter nodules, it can quickly confirm the presence of gross metastatic disease, guiding the immediate next steps in the workup. Its primary advantage is its extremely low radiation dose (ACR Relative Radiation Level ☢ <0.1 mSv), a critical consideration for a young patient population that will undergo repeated imaging over many years of surveillance.

Several other studies are also rated highly but are not recommended as the first-line test in this specific context:

  • CT chest with IV contrast: This study is also rated Usually appropriate. It is far more sensitive than radiography for small nodules and provides detailed evaluation of the mediastinum and hila. However, it imparts a significantly higher radiation dose (☢☢☢ 1-10 mSv). It is typically reserved as the next step after an abnormal or equivocal chest radiograph, or if clinical suspicion (e.g., rapidly rising markers) is very high despite a normal radiograph.
  • FDG-PET/CT whole body: This is rated as May be appropriate. While useful for assessing treatment response or evaluating residual masses post-chemotherapy, it is not the preferred initial modality for suspected recurrence. It involves a very high radiation dose (☢☢☢☢ 10-30 mSv) and has a higher potential for false-positive findings from inflammatory or infectious causes.

Starting with a chest radiograph is a logical, low-impact first step. It can rapidly identify pulmonary disease and directs a more targeted, and often necessary, subsequent workup with cross-sectional imaging.

What’s Next After a Chest Radiograph? Downstream Workflow

The results of the initial chest radiograph will dictate the subsequent diagnostic pathway. The goal is to move efficiently toward full re-staging if recurrence is found, or to confidently rule it out if the findings are negative.

If the Radiograph is Positive
If the chest radiograph reveals a suspicious nodule, mass, or adenopathy, the immediate next step is to obtain a `CT chest with IV contrast`. This will confirm and characterize the findings, detect any additional, smaller lesions missed on the radiograph, and evaluate the mediastinum. Concurrently or immediately following, a `CT abdomen and pelvis with IV contrast` is required to evaluate the retroperitoneum, the most common site of relapse. Both of these CT studies are rated Usually appropriate for this purpose and are essential for complete re-staging to guide further treatment.

If the Radiograph is Negative
A negative chest radiograph is reassuring but does not end the workup, especially if the suspicion for recurrence was driven by rising tumor markers or non-pulmonary symptoms (e.g., back pain). In this case, the focus shifts to the abdomen and pelvis. The next step is a `CT abdomen and pelvis with IV contrast` to search for retroperitoneal lymphadenopathy. If this study is also negative and markers continue to rise, the case warrants a multidisciplinary discussion.

If the Radiograph is Indeterminate
Findings such as a focal opacity that could represent infection, atelectasis, or an early metastasis are considered indeterminate. A short-term follow-up radiograph in 2-4 weeks after a course of antibiotics may be considered if infection is likely. However, in the setting of rising tumor markers or high clinical suspicion, proceeding directly to a `CT chest with IV contrast` is the more prudent approach to resolve the ambiguity quickly.

Pitfalls to Avoid (and When to Get Help)

Navigating the workup for suspected testicular cancer recurrence requires careful interpretation of clinical signs and imaging results. Here are a few common pitfalls to avoid:

  • Stopping the Workup Prematurely: A normal chest radiograph does not rule out recurrence. The retroperitoneum is the most common site of relapse and must be evaluated with cross-sectional imaging if tumor markers are rising or other symptoms are present.
  • Misinterpreting Tumor Markers: Relying solely on imaging without correlating with serial tumor marker trends can be misleading. Persistently rising markers in the face of negative imaging is a known clinical challenge that requires expert consultation.
  • Inappropriate Use of PET/CT: Ordering a PET/CT as the first-line imaging study is generally not indicated. It exposes the patient to high radiation and is better reserved for specific problem-solving scenarios, such as characterizing a residual mass after chemotherapy.

If imaging findings are negative but tumor markers continue to rise, or if the clinical picture is complex, it is essential to escalate. This typically involves referral back to the patient’s oncologist and discussion at a multidisciplinary genitourinary tumor board.

Related ACR Topics and Tools

This article covers a single, specific clinical scenario. For a comprehensive overview of all variants related to imaging for testicular cancer, from initial staging to different surveillance protocols, please consult our parent topic hub article. For further exploration of imaging guidelines and tools, the following resources are available:

Frequently Asked Questions

Why not just order a CT of the chest, abdomen, and pelvis from the start?

While a comprehensive CT is often the eventual endpoint if recurrence is found, starting with a chest radiograph is a more judicious, stepwise approach. It minimizes initial radiation exposure, which is a key principle in managing young cancer survivors. If the radiograph is positive, it confirms the need for further imaging, and if negative, it helps guide the next step (CT of the abdomen/pelvis) without having exposed the chest to unnecessary radiation if the recurrence is isolated to the retroperitoneum.

What if the patient’s tumor markers (AFP, β-hCG) are rising but the chest radiograph is normal?

This is a very common and important scenario. A normal chest radiograph does not rule out recurrence. The next step is to immediately proceed with a CT of the abdomen and pelvis with IV contrast. The retroperitoneum is the most likely site of disease in a patient with rising markers and a normal chest X-ray.

Is an MRI a good alternative to CT for evaluating the abdomen and pelvis in this scenario?

According to the ACR, MRI of the abdomen and pelvis with and without IV contrast is also rated ‘Usually appropriate’ and is an excellent alternative to CT. It avoids ionizing radiation, which is a significant benefit. However, CT is often faster, more widely available, and may be preferred by some institutions for its high spatial resolution and standardized protocols for lymph node assessment. The choice between CT and MRI can depend on institutional preference, patient factors (like renal function or contrast allergies), and radiologist expertise.

When is a PET/CT scan the right choice in testicular cancer surveillance?

FDG-PET/CT is rated ‘May be appropriate’ in this scenario but is generally reserved for specific, complex situations rather than initial evaluation of suspected recurrence. Its primary role in testicular cancer is in assessing residual retroperitoneal masses after chemotherapy, particularly in seminoma patients, to determine if the mass represents active tumor or benign fibrotic/necrotic tissue. It is not recommended as a first-line screening tool for recurrence due to its high radiation dose and lower specificity compared to CT.

Does this workflow apply if the patient has pure seminoma versus nonseminoma?

Yes, this specific ACR variant and the recommended workflow apply to both pure seminoma and nonseminomatous germ cell tumors (NSGCTs) in stage IA and IB. While their patterns of marker elevation and response to therapy differ, the initial imaging approach to a suspected recurrence is the same, focusing first on the most common sites of metastatic spread: the lungs and the retroperitoneum.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 29, 2026